European Association for the Study of the Liver Hepatocellular Carcinoma summit 2014: Old questions, new (or few) answers?

Future Oncology

Volumn 10, Issue 10, 2014, Pages 1719-1721

  Sacco, Rodolfo ^a   Gadaleta Caldarola, Gennaro ^b   Galati, Giovanni ^c   Lombardi, Giuseppe ^d   Mazza, GianCarlo ^e   Cabibbo, Giuseppe ^f  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b R Dimiccoli Hospital Department of Gaastroenterology   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e University of Palermo ^*  (Italy)

^f UNIVERSITY OF PALERMO   (Italy)

Author keywords

cost effectiveness; disease management; HCC; locoregional treatments; sorafenib; transarterial chemoembolization

Indexed keywords

ANTIVIRUS AGENT; BRIVANIB; CANCER VACCINE; CONTRAST MEDIUM; DOXORUBICIN; EVEROLIMUS; LINIFANIB; RAMUCIRUMAB; RESMINOSTAT; SORAFENIB; SUNITINIB; TIVANTINIB;

CANCER DIAGNOSIS; CANCER STEM CELL; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; DIFFUSION WEIGHTED IMAGING; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG EFFICACY; EUROPEAN; FOLLOW UP; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MEDICAL HISTORY; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PATIENT SELECTION; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS;

EID: 84907926843     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.102     Document Type: Review

References (16)

1. Sacco R, Gadaleta-Caldarola G, Galati G et al. EASL HCC Summit-liver cancer management. Future Oncol. 10(7), 1129-1132 (2014).
2. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-Analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 51(4), 1274-1283 (2010).
3. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 334(11), 693-639 (1996).
4. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin. Liver Dis. 19(3), 329-338 (1999).
5. Cabibbo G, Maida M, Genco C et al. Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response. PLoS ONE 8(7), e70016 (2013).
6. Llovet JM, Ricci S, Mazzaferro V et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378-390 (2008).
7. Roberts LR. Sorafenib in liver cancer-just the beginning. N. Engl. J. Med. 359(4), 420-422 (2008).
8. Garattini S, Bertele V. Non-inferiority trials are unethical because they disregard patients' interests. Lancet 370(9602), 1875-1877 (2007).
9. Cabibbo G, Rolle E, De Giorgio M et al.; HCC Working Group. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. Expt. Rev. Anticancer Ther. 11(12), 1807-1816 (2011).
10. Pawlik TM, Reyes DK, Cosgrove D et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J. Clin. Oncol. 29(30), 3960-3967 (2011).
11. Cabrera R, Pannu DS, Caridi J et al. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment. Pharmacol. Ther. 34(2), 205-213 (2011).
12. Lencioni R, Llovet JM, Han G et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial. J. Clin. Oncol. 30(Suppl. 4), Abstract LBA154 (2012).
13. Borzio M, Sacco R. Nonadherence to guidelines in the management of hepatocellular carcinoma: An Italian or universal phenomenon?. Future Oncol. 9(4), 465-467 (2013).
14. D'Angelo S, Secondulfo M, De Cristofano R, Sorrentino P. Sorafenib and Entecavir: The Dioscuri of Treatment for Advanced Hepatocellular Carcinoma?. World J. Gastroenterol. 19(14), 2141-2143 (2013).
15. Sacco R. Use of entecavir for the treatment of complex forms of Hepatitis B. Eur. Rev. Med. Pharm. Sci. 18(9), 1333-1343 (2014).
16. Petta S, Cabibbo G, Enea M et al.; WEF Study Group. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 59(5), 1692-1705 (2014).